Omeros (OMER) Stock Forecast & Price Target

Omeros is taking steps to expand their commercial opportunities and partnerships in the U.S., including their YARTEMLEA product and partnership with NVO, which has the potential to reward shareholders. The negative opinion on their EU application does not rule out eventual approval and the ongoing AZN readout is seen more as a clearing event than a major risk to the company's dominant position in TA-TMA due to YARTEMLEA's strong early launch, differentiated mechanism, and favorable safety profile compared to C5 inhibitors. The company has a strong pipeline with multiple promising programs, including OMS1029 and OMS527, providing additional value potential in the future. Additional risks to consider include regulatory, clinical development, intellectual property, and future pipeline candidates, but overall, Omeros remains well-positioned for growth and profitability in the coming years as they expand their commercial reach and advance their pipeline.

Omeros is facing a potential overhang on its stock due to the upcoming data readout for AZN’s Ultomiris/ravulizumabTA-TMA, which could come as early as around EHA 2026 (June 11–14) or potentially around ISTH 2026 (July 11–15). However, the market may be over-discounting the risk of a positive reading, which could improve reimbursement for ravulizumab but not necessarily impair YARTEMLEA’s commercial trajectory given its strong early launch, first-approved status, and favorable physician feedback. Additionally, the assignation of a permanent J-code and NTAP approval by CMS, along with strong uptake metrics and broad formulary access, suggest that YARTEMLEA has the potential to become the standard of care for TA-TMA and could pave the way for expansion into other indications.